{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T06:37:55Z","timestamp":1791095875892,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00228-010-0810-9","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T12:42:07Z","timestamp":1269952927000},"page":"579-590","source":"Crossref","is-referenced-by-count":30,"title":["Explaining variability in ciclosporin exposure in adult kidney transplant recipients"],"prefix":"10.1007","volume":"66","author":[{"given":"Rogier R.","family":"Press","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart A.","family":"Ploeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"den Hartigh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"van der Straaten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"van Pelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meindert","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,31]]},"reference":[{"key":"810_CR1","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Tedesco-Silva H, Demirbas A et al (2007) Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 357:2562\u20132575","journal-title":"N Engl J Med"},{"key":"810_CR2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007890-199907150-00011","volume":"68","author":"K Mahalati","year":"1999","unstructured":"Mahalati K, Belitsky P, Sketris I, West K, Panek R (1999) Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68:55\u201362","journal-title":"Transplantation"},{"key":"810_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0163-7258(89)90025-9","volume":"42","author":"MA McMillan","year":"1989","unstructured":"McMillan MA (1989) Clinical pharmacokinetics of cyclosporin. Pharmacol Ther 42:135\u2013156","journal-title":"Pharmacol Ther"},{"key":"810_CR4","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/ndt\/gfg065","volume":"18","author":"SC Cremers","year":"2003","unstructured":"Cremers SC, Scholten EM, Schoemaker RC, Lentjes EG, Vermeij P, Paul LC, den Hartigh J, de Fijter JW (2003) A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. Nephrol Dial Transplant 18:1201\u20131208","journal-title":"Nephrol Dial Transplant"},{"key":"810_CR5","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/01.tp.0000268306.41196.2c","volume":"83","author":"SR Knight","year":"2007","unstructured":"Knight SR, Morris PJ (2007) The clinical benefits of cyclosporine C2-level monitoring: a systematic review. Transplantation 83:1525\u20131535","journal-title":"Transplantation"},{"key":"810_CR6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00003088-200241090-00001","volume":"41","author":"F Akhlaghi","year":"2002","unstructured":"Akhlaghi F, Trull AK (2002) Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 41:615\u2013637","journal-title":"Clin Pharmacokinet"},{"key":"810_CR7","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1023\/A:1012190620854","volume":"14","author":"KM Wasan","year":"1997","unstructured":"Wasan KM, Pritchard PH, Ramaswamy M, Wong W, Donnachie EM, Brunner LJ (1997) Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm Res 14:1613\u20131620","journal-title":"Pharm Res"},{"key":"810_CR8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/01.ftd.0000148448.51225.2c","volume":"27","author":"SE Rosenbaum","year":"2005","unstructured":"Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F (2005) Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 27:116\u2013122","journal-title":"Ther Drug Monit"},{"key":"810_CR9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ndt\/5.5.376","volume":"5","author":"CS Ubhi","year":"1990","unstructured":"Ubhi CS, Woodhouse L, Giles GR (1990) Interaction of intravenous methylprednisolone with oral cyclosporin. Nephrol Dial Transplant 5:376\u2013378","journal-title":"Nephrol Dial Transplant"},{"key":"810_CR10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0009-9236(95)90032-2","volume":"57","author":"MP Ducharme","year":"1995","unstructured":"Ducharme MP, Warbasse LH, Edwards DJ (1995) Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 57:485\u2013491","journal-title":"Clin Pharmacol Ther"},{"key":"810_CR11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/clpt.1992.171","volume":"52","author":"MF Hebert","year":"1992","unstructured":"Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ (1992) Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 52:453\u2013457","journal-title":"Clin Pharmacol Ther"},{"key":"810_CR12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","volume":"62","author":"KS Lown","year":"1997","unstructured":"Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248\u2013260","journal-title":"Clin Pharmacol Ther"},{"key":"810_CR13","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/j.1600-6143.2004.00539.x","volume":"4","author":"WP Lemahieu","year":"2004","unstructured":"Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem Y (2004) CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 4:1514\u20131522","journal-title":"Am J Transplant"},{"key":"810_CR14","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1389200054633880","volume":"6","author":"J Lamba","year":"2005","unstructured":"Lamba J, Lamba V, Schuetz E (2005) Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6:369\u2013383","journal-title":"Curr Drug Metab"},{"key":"810_CR15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00008571-200110000-00003","volume":"11","author":"J Zhang","year":"2001","unstructured":"Zhang J, Kuehl P, Green ED et al (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555\u2013572","journal-title":"Pharmacogenetics"},{"key":"810_CR16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/0091270007299930","volume":"47","author":"BL Urquhart","year":"2007","unstructured":"Urquhart BL, Tirona RG, Kim RB (2007) Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 47:566\u2013578","journal-title":"J Clin Pharmacol"},{"key":"810_CR17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/00007691-200404000-00019","volume":"26","author":"L Wojnowski","year":"2004","unstructured":"Wojnowski L (2004) Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 26:192\u2013199","journal-title":"Ther Drug Monit"},{"key":"810_CR18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T (2003) Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245\u2013254","journal-title":"Clin Pharmacol Ther"},{"key":"810_CR19","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.clpt.2004.01.009","volume":"75","author":"D Anglicheau","year":"2004","unstructured":"Anglicheau D, Thervet E, Etienne I et al (2004) CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75:422\u2013433","journal-title":"Clin Pharmacol Ther"},{"key":"810_CR20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.TP.0000136256.56873.41","volume":"78","author":"D Anglicheau","year":"2004","unstructured":"Anglicheau D, Legendre C, Thervet E (2004) Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. Transplantation 78:311\u2013315","journal-title":"Transplantation"},{"key":"810_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","volume":"14","author":"V Haufroid","year":"2004","unstructured":"Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147\u2013154","journal-title":"Pharmacogenetics"},{"key":"810_CR22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14622416.6.4.323","volume":"6","author":"DA Hesselink","year":"2005","unstructured":"Hesselink DA, van Gelder T, van Schaik RH (2005) The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics 6:323\u2013337","journal-title":"Pharmacogenomics"},{"key":"810_CR23","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF01062270","volume":"18","author":"MO Karlsson","year":"1990","unstructured":"Karlsson MO, Lindberg-Freijs A (1990) Comparison of methods to calculate cyclosporine A bioavailability from consecutive oral and intravenous doses. J Pharmacokinet Biopharm 18:293\u2013311","journal-title":"J Pharmacokinet Biopharm"},{"key":"810_CR24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"810_CR25","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1208\/ps040427","volume":"4","author":"U Wahlby","year":"2002","unstructured":"Wahlby U, Jonsson EN, Karlsson MO (2002) Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4:E27","journal-title":"AAPS PharmSci"},{"key":"810_CR26","volume-title":"NONMEM users guide (1989\u20132006)","author":"SL Beal","year":"2006","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ (2006) NONMEM users guide (1989\u20132006). Icon Development Solutions, Ellicott City, MD"},{"key":"810_CR27","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","volume":"28","author":"U Wahlby","year":"2001","unstructured":"Wahlby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231\u2013252","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"810_CR28","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185\u2013202","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"810_CR29","first-page":"355","volume-title":"Pharmacokinetic-pharmacodynamic modeling and simulation","author":"PL Bonate","year":"2006","unstructured":"Bonate PL (2006) Pharmacokinetic-pharmacodynamic modeling and simulation. Springer, New York, pp 355\u2013364"},{"key":"810_CR30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14622416.6.1.37","volume":"6","author":"E Thervet","year":"2005","unstructured":"Thervet E, Legendre C, Beaune P, Anglicheau D (2005) Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 6:37\u201347","journal-title":"Pharmacogenomics"},{"key":"810_CR31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1517\/14622416.6.2.163","volume":"6","author":"T Szekeres","year":"2005","unstructured":"Szekeres T, Haushofer A (2005) Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. Pharmacogenomics 6:163\u2013168","journal-title":"Pharmacogenomics"},{"key":"810_CR32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10928-009-9124-x","volume":"36","author":"J Bertrand","year":"2009","unstructured":"Bertrand J, Comets E, Laffont CM, Chenel M, Mentre F (2009) Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm. J Pharmacokinet Pharmacodyn 36:317\u2013339","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"810_CR33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FPC.0b013e3282f3ef72","volume":"18","author":"S Fanta","year":"2008","unstructured":"Fanta S, Niemi M, Jonsson S, Karlsson MO, Holmberg C, Neuvonen PJ, Hoppu K, Backman JT (2008) Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 18:77\u201390","journal-title":"Pharmacogenet Genomics"},{"key":"810_CR34","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/j.1552-4604.1994.tb03967.x","volume":"34","author":"FT Aweeka","year":"1994","unstructured":"Aweeka FT, Tomlanovich SJ, Prueksaritanont T, Gupta SK, Benet LZ (1994) Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients. J Clin Pharmacol 34:60\u201367","journal-title":"J Clin Pharmacol"},{"key":"810_CR35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1124\/mol.58.2.361","volume":"58","author":"JM Pascussi","year":"2000","unstructured":"Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ (2000) Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol 58:361\u2013372","journal-title":"Mol Pharmacol"},{"key":"810_CR36","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1046\/j.0014-2956.2001.02540.x","volume":"268","author":"JM Pascussi","year":"2001","unstructured":"Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268:6346\u20136358","journal-title":"Eur J Biochem"},{"key":"810_CR37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","volume":"31","author":"RR Press","year":"2009","unstructured":"Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, de Fijter JW, Guchelaar HJ (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 31:187\u2013197","journal-title":"Ther Drug Monit"},{"key":"810_CR38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1345\/aph.1K628","volume":"42","author":"S Lam","year":"2008","unstructured":"Lam S, Partovi N, Ting LS, Ensom MH (2008) Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 42:1037\u20131047","journal-title":"Ann Pharmacother"},{"key":"810_CR39","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1211\/0022357044481","volume":"56","author":"H Konishi","year":"2004","unstructured":"Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A (2004) Decrease in oral bioavailability of ciclosporin by intravenous pulse of methylprednisolone succinate in rats. J Pharm Pharmacol 56:1259\u20131266","journal-title":"J Pharm Pharmacol"},{"key":"810_CR40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1211\/0022357023114","volume":"56","author":"H Konishi","year":"2004","unstructured":"Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A (2004) Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. J Pharm Pharmacol 56:477\u2013483","journal-title":"J Pharm Pharmacol"},{"key":"810_CR41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2125.1992.tb03998.x","volume":"33","author":"J Drewe","year":"1992","unstructured":"Drewe J, Beglinger C, Kissel T (1992) The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 33:39\u201343","journal-title":"Br J Clin Pharmacol"},{"key":"810_CR42","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1476-5381.1996.tb15346.x","volume":"117","author":"A Lampen","year":"1996","unstructured":"Lampen A, Christians U, Gonschior AK, Bader A, Hackbarth I, von Engelhardt W, Sewing KF (1996) Metabolism of the macrolide immunosuppressant, tacrolimus, by the pig gut mucosa in the Ussing chamber. Br J Pharmacol 117:1730\u20131734","journal-title":"Br J Pharmacol"},{"key":"810_CR43","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","volume":"66","author":"J Liu","year":"1991","unstructured":"Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807\u2013815","journal-title":"Cell"},{"key":"810_CR44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/00007691-200410000-00008","volume":"26","author":"H Zahir","year":"2004","unstructured":"Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ (2004) Changes in tacrolimus distribution in blood and plasma protein binding following liver transplantation. Ther Drug Monit 26:506\u2013515","journal-title":"Ther Drug Monit"},{"key":"810_CR45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2125.2003.02008.x","volume":"57","author":"H Zahir","year":"2004","unstructured":"Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ (2004) Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 57:298\u2013309","journal-title":"Br J Clin Pharmacol"},{"key":"810_CR46","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404\u2013430","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0810-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T18:15:26Z","timestamp":1551291326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0810-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,31]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["810"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0810-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,31]]}}}